From simple body mass index to lifesaving action: Linking low muscle mass, late diagnosis, and survival in chemoradiotherapy-treated esophageal cancer
World Journal of Clinical Oncology · 24.06.2026 · 17 (6)
DOI: 10.5306/wjco.119908 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.06.2026. Verfasst von Sara Cristina González und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
In the challenging landscape of esophageal squamous cell carcinoma (ESCC), where late diagnosis often brings progressive dysphagia, feeding difficulties, and chronic caloric-protein deficits that accelerate muscle wasting even before treatment begins, Xiao et al offer a compelling insight in the World Journal of Clinical Oncology . Their retrospective analysis of 360 patients undergoing definitive chemoradiotherapy reveals that baseline body mass index (BMI) is a powerful, readily available predictor of low muscle mass (LMM). Each additional BMI unit is linked to roughly a 39% lower odds of LMM (odds ratio: 0.613; 95%CI: 0.531-0.707), with a clear inflection point around 21.5 kg/m2 marking heightened risk below this threshold. What truly stands out is the synergistic prognostic impact: Patients burdened by both low BMI and LMM face the bleakest outlook, with a median overall survival of only 17 months. This underscores that LMM is far more than a nutritional byproduct — it acts as an independent driver of poorer treatment tolerance, heightened toxicities, and reduced survival in locally advanced ESCC. These observations open a practical window for action in everyday oncology practice. A simple BMI measurement at diagnosis can serve as an immediate, zero-cost alert to prompt detailed body composition evaluation (ideally via pretreatment computed tomography) and swift multidisciplinary intervention. Early nutritional reinforcement — through hypercaloric, high-protein oral nutritional supplements (ONS) delivering ≥ 1.5-2.0 g protein/kg ideal body weight daily — has been shown in dedicated trials to preserve weight, BMI, albumin, and prealbumin levels while attenuating radiation esophagitis, myelosuppression, and other toxicities during radiotherapy or chemoradiotherapy in ESCC patients. Meta-analyses further support that high-protein ONS reduces complications and aids lean mass maintenance in high-sarcopenia-risk cancers such as esophageal cancer. When oral intake falters due to tumor-related dysphagia, enteral routes become essential, complemented by individualized dietitian guidance and frequent reassessments. Adding supervised resistance training (2-3 sessions/week) where performance status allows provides a vital non-nutritional countermeasure against sarcopenia progression. By viewing BMI and LMM not merely as prognostic signals but as modifiable targets, we can shift toward more proactive, personalized supportive care — potentially transforming outcomes in one of oncology’s most demanding diseases.
Zitieren
APA
González, S. C., Ramirez, C. A., Holgado, E., & Couñago, F. (2026). From simple body mass index to lifesaving action: Linking low muscle mass, late diagnosis, and survival in chemoradiotherapy-treated esophageal cancer. World Journal of Clinical Oncology, 17(6). https://doi.org/10.5306/wjco.119908
Vancouver
González SC, Ramirez CA, Holgado E, Couñago F. From simple body mass index to lifesaving action: Linking low muscle mass, late diagnosis, and survival in chemoradiotherapy-treated esophageal cancer. World Journal of Clinical Oncology. 2026;17(6). doi:10.5306/wjco.119908
BibTeX
@article{Gonzlez2026,
author = {González, Sara Cristina and Ramirez, Carmen Aida and Holgado, Esther and Couñago, Felipe},
title = {From simple body mass index to lifesaving action: Linking low muscle mass, late diagnosis, and survival in chemoradiotherapy-treated esophageal cancer},
journal = {World Journal of Clinical Oncology},
year = {2026},
volume = {17},
number = {6},
doi = {10.5306/wjco.119908}
}
EUVIMED